You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Dow
Johnson and Johnson
Moodys
Boehringer Ingelheim

Last Updated: February 23, 2024

ZEMBRACE SYMTOUCH Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Zembrace Symtouch, and when can generic versions of Zembrace Symtouch launch?

Zembrace Symtouch is a drug marketed by Tonix Meds and is included in one NDA. There are two patents protecting this drug.

This drug has six patent family members in six countries.

The generic ingredient in ZEMBRACE SYMTOUCH is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Zembrace Symtouch

A generic version of ZEMBRACE SYMTOUCH was approved as sumatriptan succinate by WEST-WARD PHARMS INT on February 6th, 2009.

  Try a Trial

US Patents and Regulatory Information for ZEMBRACE SYMTOUCH

ZEMBRACE SYMTOUCH is protected by two US patents.

Patents protecting ZEMBRACE SYMTOUCH

Pharmaceutical composition for treating migraine
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF MIGRAINE

Pharmaceutical composition for treating migraine
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF MIGRAINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Tonix Meds ZEMBRACE SYMTOUCH sumatriptan succinate SOLUTION;SUBCUTANEOUS 208223-001 Jan 28, 2016 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Tonix Meds ZEMBRACE SYMTOUCH sumatriptan succinate SOLUTION;SUBCUTANEOUS 208223-001 Jan 28, 2016 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ZEMBRACE SYMTOUCH

See the table below for patents covering ZEMBRACE SYMTOUCH around the world.

Country Patent Number Title Estimated Expiration
Mexico 2018001528 COMPOSICION FARMACEUTICA QUE COMPRENDE SUMATRIPTAN PARA TRATAMIENTO DE MIGRAÑA. (PHARMACEUTICAL COMPOSITION COMPRISING SUMATRIPAN FOR TREATING MIGRAINE.) ⤷  Try a Trial
China 107921023 用于治疗偏头痛的包含舒马曲坦的药物组合物 (Pharmaceutical composition comprising sumatripan for treating migraine) ⤷  Try a Trial
Brazil 112018002433 composição farmacêutica para tratamento da enxaqueca ⤷  Try a Trial
European Patent Office 3331524 COMPOSITION PHARMACEUTIQUE COMPRENANT DU SUMATRIPTAN POUR LE TRAITEMENT DE LA MIGRAINE (PHARMACEUTICAL COMPOSITION COMPRISING SUMATRIPAN FOR TREATING MIGRAINE) ⤷  Try a Trial
World Intellectual Property Organization (WIPO) 2017023361 ⤷  Try a Trial
Canada 2994748 COMPOSITION PHARMACEUTIQUE COMPRENANT DU SUMATRIPTAN POUR LE TRAITEMENT DE LA MIGRAINE (PHARMACEUTICAL COMPOSITION COMPRISING SUMATRIPAN FOR TREATING MIGRAINE) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Merck
Colorcon
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.